PetVivo Holdings, Inc. reported financial results for the fiscal year ended March 31, 2026, and the fourth quarter, highlighting a net loss of $10,877,275 for the full year compared to a net loss of $8,399,166 in the prior year. The company, a provider of medical devices and biomedical therapeutics for equines and companion animals, recorded revenue of $1,141,607 for fiscal 2026, up from $1,132,533 in fiscal 2025. For the fourth quarter, sales reached $254.715 thousand, a 13.33 percent increase from $224.750 thousand in the same period last year, while quarterly losses remained unchanged at $(0.11) per share.

Fiscal 2026 Financial Performance

PetVivo reported a net loss available to common stockholders of $10,877,275, or $(0.38) per share, for the year ended March 31, 2026. This compares to a net loss available to common stockholders of $8,399,166, or $(0.41) per share, for the year ended March 31, 2025. Operating expenses for the year totaled $9,817,713, an increase from $9,050,575 in the prior year, driven by higher sales and marketing costs of $3,069,104 and general and administrative expenses of $4,333,577.

Operational Highlights and Strategic Developments

During the fourth quarter, Health Canada officially recognized PetVivo’s Spryng with OsteoCushion Technology as a veterinary medical device authorized for commercialization in Canada. The company believes Spryng is among the first hydrogel-based intra-articular injectable veterinary medical devices to receive this recognition, with a commercial launch expected near the end of July. Additionally, the company advanced its partnership with Veterinary Growth Partners, which promotes Spryng to a network of over 7,300 veterinary clinics.

PetVivo’s AI technology partner, Digital Landia, launched the public beta of AgenticPet, a B2C solution for pet owners. The platform secured 1,000 active beta users in less than 72 hours. The company also advanced the commercial rollout of PetVivo.ai, a Software-as-a-Service veterinary-practice platform, which demonstrated a 50% to 90% reduction in customer acquisition costs during its beta program.

Acquisition of PiezoBioMembrane

On June 24, 2026, PetVivo announced the acquisition of PiezoBioMembrane (PMB), its R&D partner and developer of patented functional biomaterials. As a wholly-owned subsidiary, PMB will focus on the development and commercialization of next-generation biomaterials and regenerative therapeutic technologies. The acquisition is subject to customary closing conditions, including the completion of due diligence and financing activities. The companies plan to pursue FDA clearance for products incorporating PMB’s piezoelectric materials for human applications.

Conference Call Details

PetVivo management hosted a conference call to discuss the fiscal year’s financial and operational results on June 29, 2026. A replay of the webcast is available on the company’s Investor Relations website.

PetVivo Holdings, Inc. has entered into an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM), a developer of advanced functional biomaterials and piezoelectric technologies. The transaction, announced on June 24, 2026, will see PBM become a wholly owned subsidiary of Cosmeta Corp., PetVivo's wholly owned operating subsidiary. This acquisition is designed to strengthen PetVivo's intellectual property portfolio and create new opportunities for medical device and therapeutic product development across animal and human health markets.

Under the terms of the merger agreement, PBM shareholders will receive an aggregate of 3,000,000 shares of PetVivo common stock. A portion of this consideration is subject to milestone-based retention and forfeiture provisions aimed at aligning future value creation with the achievement of key development and regulatory objectives. The transaction remains subject to customary closing conditions, including the completion of due diligence, satisfaction of specified closing obligations, and the execution of related transaction documents.

The acquisition provides PetVivo with access to PBM's technology platform, which includes proprietary know-how, licensed intellectual property rights, patents, patent applications, and trade secrets. Additionally, PetVivo will gain control of biomaterials, formulations, regulatory assets, manufacturing information, and clinical information. These assets are intended to support the development of functional biomaterials, medical devices, and other therapeutic applications.

John Lai, Chief Executive Officer of PetVivo Holdings, stated that the transaction represents a transformative step in the company's long-term growth strategy. He noted that combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, and regulatory expertise could accelerate the advancement of technologies. Lai also highlighted the potential for the combined platform to secure grant funding, research collaborations, and research and development tax credit programs.

Thanh Nguyen, President of PiezoBioMembrane, described the transaction as an exciting milestone reflecting years of scientific development and innovation. He emphasized that PBM has established a functional biomaterials platform with opportunities across a broad range of medical device and therapeutic applications. Nguyen expressed confidence that combining PBM's technology with PetVivo's capabilities would accelerate future product development and maximize the value of the available intellectual property rights.

Transaction Details

The transaction also establishes a framework for the continued involvement of key PBM personnel in advancing the technology platform and achieving development milestones following the closing. The parties expect the combined resources of PBM, Cosmeta, and PetVivo to accelerate product development activities, regulatory advancement, strategic collaborations, and commercialization initiatives.